Completed PHASE1 INTERVENTIONAL NCT00270452

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Safety of WT1 and PR1 Peptide Vaccination for Patients With Myeloid Malignancies

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Myelodysplastic Syndrome (MDS)

Interventions WT1 and PR1 Peptide Vaccine

Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Dec 22, 2005 Primary completion: Oct 26, 2007 Completion: Oct 26, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00270452, this PHASE1 trial focuses on Myelodysplastic Syndrome (MDS) and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States